Printer Friendly

InSite Vision to Report Fourth Quarter and Year-End 2012 Financial Results on March 5, 2013.

ALAMEDA, Calif. -- InSite Vision Incorporated (OTCBB: INSV) announced today that it will report financial results for the fourth quarter and year ended December 31, 2012 on Tuesday, March 5, 2013.

Company management will host a conference call that day beginning at 4:30 p.m. ET/1:30 p.m. PT to discuss fourth quarter and full year 2012 financial results and to review recent accomplishments and upcoming milestones. Investors will be invited to ask questions following management's prepared remarks.

Analysts and investors can participate in the conference call by dialing 888-680-0893 for domestic callers and 617-213-4859 for international callers using the pass code 55013640. A telephone replay will be available following the conclusion of the call by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers using the pass code 60004268.

The live conference call will also be webcast and available on the Investor Relations page of the company's website at A press release detailing fourth quarter and full year 2012 financial results will be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K.

About InSite Vision

InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite([R]) platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.

The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite([R]) (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance([R]) (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus([TM]) and DexaSite([TM]) for the treatment of eye infections, and BromSite[TM] for pain and inflammation associated with ocular surgery. For further information on InSite Vision, please visit

AzaSite([R]), DuraSite([R])and DuraSite 2[R]are registered trademarks of InSite Vision Incorporated. AzaSite Plus([TM]), BromSite([TM]) and DexaSite([TM]) are trademarks of InSite Vision Incorporated. BESIVANCE([R]) is a registered trademark of Bausch + Lomb Incorporated.
COPYRIGHT 2013 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Financial report
Geographic Code:1U9CA
Date:Feb 19, 2013
Previous Article:Leading Alternative Fuel Developers Set to Ramp Revenues.
Next Article:Equity Loans LLC Leverages Advantage Systems' Accounting to Support a 300 Percent Increase in Loan Production.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters